Articles tagged with Parkinsons Disease
A new hypothesis paper proposes that Parkinson's disease starts in either the brain's smell center or the body's intestinal tract, tied to environmental factors. The study suggests that exposure to pesticides, air pollution, and tainted food may predispose to the disease.
A groundbreaking clinical study demonstrates the potential of fecal microbiota transplantation (FMT) to improve symptoms in patients with Parkinson's disease. After 12 months, participants who received healthy donor stool transplants showed significant improvement in motor symptoms and reduced constipation.
The study found that crowding and salt enhance the aggregation of alpha-synuclein, while also stabilizing the resulting aggregates. The simulations revealed that certain amino acids exist to prevent aggregation and that proteins orient themselves to minimize interactions between these residues.
A Rice University research project aims to provide new insights into biological fibrillar nanostructures with potential implications for the treatment and diagnosis of Alzheimer’s and Parkinson’s diseases.
Researchers discovered Lewy body disease changes in 9% of people over 50 without a clinical diagnosis, suggesting the disease may be more common than thought. Further studies are needed to confirm the results, but early detection is crucial for effective therapies.
Research finds that supplementing propionate suppresses neurodegeneration in animal models of Parkinson's disease by regulating interorgan signalling. Increasing propionate levels rescues transcriptional aberration and enhances energy production, promoting neuronal health without protein aggregate dispersal.
A team of researchers has developed the world's first 3D-printed brain phantom, which can be imaged using dMRI. The brain model is made up of microchannels that mimic nerve cells in the brain, allowing for more accurate analysis and research into neurodegenerative diseases.
A skin biopsy test detects abnormal alpha-synuclein protein in patients with Parkinson's disease, dementia with Lewy bodies, and related disorders. The test showed high accuracy rates, validating its reliability for early diagnosis and clinical drug development.
Researchers at the University of Galway have developed a new method for improving stem cell-based brain repair therapy for Parkinson's disease, which shows promising results in enhancing survival and maturation of cells in the brain. The technique uses a collagen hydrogel to support and protect the cells after transplantation.
A new study by researchers at the University of Minnesota reveals that non-invasive brain stimulation can change a specific brain mechanism related to human behavior. The technique, called transcranial alternating current stimulation, modulates brain activity by shifting when brain cells are active.
A phase 3 trial co-led by a University of Cincinnati researcher found that subcutaneous levodopa delivery through an infusion pump is safe and effective in reducing symptoms for longer periods. The study resulted in almost two hours of additional 'on time' compared to traditional oral medication, paving the way for potential FDA approval.
Cells use autophagy as a recycling system to transport and break down damaged organelles, including mitochondria. A recent study reveals the molecular details of how an enzyme called TBK1 participates in mitophagy, a disease-relevant process linked to Parkinson's disease.
Researchers found that people with Parkinson's disease who experience presence hallucinations overestimate the number of people in a room due to a perceptual disorder. The study used virtual reality and robotics to induce presence hallucinations and measure susceptibility, developing an online test for early detection.
The Federation of European Neuroscience Societies is open to media registration for its 2024 event. Journalists can access the latest research discoveries in neuroscience fields such as dementia, addiction and depression.
Researchers found a correlation between Parkinson's disease and freezing of gait in 20 studies, noting similar brain injury causes both symptoms. Sleep quality deteriorates when dopaminergic medication is stopped, suggesting treatment potential for freezing of gait.
Researchers found that patients with impulse control disorder (ICD) are less affected by the consequences of their actions, particularly when on medication. This suggests that ICD patients may experience positive feelings from taking risky actions based on expectations, rather than processing negative feedback.
Researchers discovered rapid calcium influx into mitochondria upon autophagy induction, coinciding with fluctuations in ER membrane calcium concentrations. Mitochondrial calcium transport may regulate mitophagy velocity, shedding light on disease mechanisms and potential therapeutic avenues for Parkinson's disease.
A small study found that tandem cycling paired with virtual reality improves the physical and emotional well-being of both participants. Care partners also showed significant improvements in resiliency and depression scores after the intervention.
A study has found a strong link between pesticide use and Parkinson's disease in the Rocky Mountain and Great Plains region. The research identified 14 pesticides, including simazine, atrazine, and lindane, that were associated with an increased risk of developing the disease.
A team of researchers used deep brain stimulation to localize disrupted neural pathways in patients with Parkinson's disease, dystonia, OCD, and Tourette's syndrome. The study identified specific brain circuits associated with each disorder, revealing overlapping malfunctions that suggest a complex network of brain dysfunctions.
Researchers discover dopamine signals affect movement sequence length, shedding light on Parkinson's Disease symptoms and potential therapeutic targets. The study's findings suggest a complex role of dopamine neurons in movement, with distinct effects on movement-related and reward-related dopamine neurons.
Researchers developed protein-like polymers to disrupt the Keap1/Nrf2 protein-protein interaction, preventing cellular damage and oxidative stress. This approach holds promise for treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Post-translational modifications on alpha-synuclein slow amyloid aggregation and protect neurons, potentially slowing disease progression. The study's findings suggest that targeting these modifications could lead to new treatments for Parkinson's disease.
Researchers have identified a network of neurons controlling right-left movements in the brain, which may help treat Parkinson's disease. The discovery provides insight into how essential movements are produced by the brain.
The Medical University of South Carolina will be one of four sites exploring the genetic basis of Parkinson’s disease in the Black community. The study, known as BLAAC PD, aims to genotype over 150,000 people worldwide and develop targeted treatments for this subtype of PD.
Researchers discuss recent advances in brain mapping, emphasizing the need to establish precise neuromodulation paradigms based on individual characteristics. Individualized brain mapping methods have evolved from manual labeling to staining techniques across multiple subjects.
Indiana University researchers have found that nicotinamide nucleotide adenylyl transferase 2 (NMNAT2) plays a critical role in protecting the brain from aging and neurodegenerative diseases. The enzyme provides energy to axons, enabling them to carry out nerve impulses and maintain healthy function.
Researchers discovered that fasting raises arachidonic acid levels, which inhibit the NLRP3 inflammasome and reduce chronic inflammation. This finding may explain how calorie restriction protects against diseases linked to Western diets.
Researchers at McGill University propose a new biological classification system for Parkinson's disease, considering alpha-synuclein, neurodegeneration, and genetics. This shift in thinking aims to diagnose the disease earlier, targeting specific patient groups with more common biology, improving treatment development success.
A new biological classification system for Parkinson's disease, known as SynNeurGe (S-N-G system), has been introduced. This classification considers three key components: pathological α-synuclein in tissues or cerebrospinal fluid, neuroimaging techniques, and pathogenic gene variants. The S-N-G system offers a detailed framework for u...
Researchers developed a wireless method to effectively reduce motor dysfunction in people with Parkinson's disease using magnetogenetics. The treatment showed improved motor function and no significant damage in and around the brain, suggesting it could be a safer alternative to traditional implanted DBS systems.
Researchers at Duke University developed an adaptive deep brain stimulation therapy for Parkinson's disease, targeting two key brain structures and using a novel self-adjusting device. The study found that this approach improved motor symptoms and reduced medication doses in six patients.
A nonrandomized controlled trial found that deep brain stimulation in advanced Parkinson disease improved mobility and maintained quality of life at 5-year follow-up. In contrast, standard-of-care medication worsened quality of life mainly due to its unfavorable effect on mobility.
The CACHE Challenge series has identified seven promising molecules with potential for new, more effective drugs for familial Parkinson's disease. The open science competition, funded by The Michael J. Fox Foundation and Conscience, used AI to predict hits and validated experimental results.
Researchers from Aarhus University discovered a newly found receptor called CD163 that appears to protect against Parkinson's disease in females. The protein is involved in the immune response and seems to exert a neuroprotective role particularly relevant in females.
Researchers discovered a previously unreported neuron type with vulnerability in Parkinson's disease, shedding light on the complexity of the disease and potential therapeutic targets. The study identified distinct transcriptomic signatures of this neuron type and found reduced RIT2 expression in Parkinson's disease patients.
A potential Parkinson's medicine, Syn-RiboTAC, targets RNA to slow or stop disease progression by preventing the buildup of toxic protein alpha-synuclein. In early studies, reducing alpha-synuclein levels by even 25% or more is therapeutically beneficial, with the compound showing good selectivity and improved brain-barrier penetration.
Researchers developed a novel test that detects single ⍺-synuclein fibrils in patient samples to identify patients with Parkinson's disease earlier. This breakthrough has the potential to create early applicable molecular diagnostics, improve clinical trials, and facilitate drug screening for neurodegenerative diseases.
Researchers at Boston University's Center for Neurorehabilitation have made two important advances that may help people with Parkinson's disease walk more smoothly. Wearable soft robotic apparel and a music-based technology were tested in studies, showing promising results in increasing walking duration and distance.
A soft, wearable robot was used to help a person living with Parkinson’s disease walk without freezing, eliminating the debilitating symptom and allowing them to regain their independence. The device provided instantaneous effects and consistently improved walking in a range of conditions.
A newly identified genetic mutation in a small protein provides significant protection against Parkinson's disease. The variant, SHLP2, is found primarily in people of European descent and reduces the risk of Parkinson's by twofold.
Scientists at St. Jude Children's Research Hospital have determined the complex structure of Parkinson’s disease-related proteins LRRK2 and Rab29, revealing how they work synergistically to cause the disease. The structures provide an atomic-scale map to trace how different mutations affect function within this complex, with implicatio...
Researchers have discovered a protein called NEMO that prevents the formation of toxic protein aggregates in Parkinson's disease. By labeling proteins for degradation and interacting with autophagy machinery, NEMO promotes the breakdown of harmful aggregates, potentially leading to new therapeutic strategies.
Researchers identified key proteins involved in the process, including mTOR and TSC2, which can be targeted to slow or halt disease progression. The study's findings suggest new therapeutic strategies to save dopaminergic neurons and alleviate motor and cognitive symptoms.
A world-first brain stimulation treatment is being developed to treat symptoms of Parkinson's disease and epilepsy using ultrasound technology. The endovascular focused ultrasound technique could significantly improve the quality of life for thousands of people living with neurological diseases.
Scientists have successfully grown neurons from stem cells that can repair damaged brain tissue after stroke, offering new hope for treatments. The technology also holds promise for studying neurodegenerative diseases like Alzheimer's, Parkinson's, and spinal cord injury.
A study published in Molecular Cell describes how bacteria build a form of ubiquitin that helps cells communicate. The research sheds light on how different enzymes impact this protein during infection, providing an important first step towards understanding its role in diseases like Parkinson's and breast cancer.
A review article links pesticide exposure to an increased risk of developing Parkinson's disease through alterations in the gut microbiota. The authors recommend reducing or replacing agrochemicals and implementing coordinated efforts to develop standardized biomarkers for gut integrity and microbiome changes.
A study found increased brain inflammation and structural changes in special operations personnel exposed to blasts, potentially increasing the risk of long-term brain-related disease. The research suggests that repetitive exposure to low-level blasts may cause brain injuries and highlights the need for better protective measures.
A new publication in Nature Communications has developed a method to produce high-purity dopamine cells from human stem cells, offering a potential therapeutic approach for treating Parkinson's disease. The research aims to reduce recovery time and minimize the risk of relapse and medication use.
A new organoid model replicates the dopaminergic system's structure, connectivity, and functionality, shedding light on its intricate functionality and potential implications for Parkinson’s disease. The model also uncovers the enduring effects of chronic cocaine exposure on the dopaminergic circuit, even after withdrawal.
UTEP researchers develop a therapy based on caffeic-acid derived from spent coffee grounds to protect brain cells from damage. The treatment has potential to prevent neurodegenerative disorders such as Alzheimer's and Parkinson's by removing free radicals and inhibiting amyloid protein aggregation.
Researchers at the University of Wisconsin-Madison have successfully generated human norepinephrine neurons from stem cells using a key protein called ACTIVIN-A. These LC-NE neurons may serve as models for disease in humans, enabling scientists to screen drugs and answer questions about neurodegeneration.
A novel study suggests that nanoparticles of polystyrene plastic can interact with the protein alpha-synuclein in the brain, promoting conditions for Parkinson's disease. This finding raises concerns about the impact of environmental factors on human biology and highlights the need for further research.
A new study has uncovered the molecular causes of a rare developmental brain condition in children, known as Autosomal Recessive ACBD6-related disorder. The research team identified defects in the acyl-CoA-binding domain-containing protein 6 (ACBD6) gene as the underlying cause, leading to delays in cognitive and motor skills development.
A UTHealth Houston researcher is leading a large-scale implementation trial to address disparities in palliative care for Parkinson's disease and related dementia patients. The study aims to reduce low-value and unequal care, improve end-of-life care, and promote health equity.
Researchers at Beth Israel Deaconess Medical Center have made a groundbreaking discovery that inhibiting a specific enzyme can halt the progression of Parkinson's disease in a mouse model. The findings suggest that reducing USP30 may slow or prevent PD progression, paving the way for novel therapeutics.
Researchers at UMass Lowell found that anti-inflammatory bacteria were less abundant in people with Parkinson's disease, suggesting a potential biomarker for early diagnosis. A new study on Latinos may also uncover novel biomarkers for Alzheimer's disease.
Researchers developed a handheld, wireless biosensor to detect Alzheimer's and Parkinson's biomarkers from saliva and urine samples. The device has shown high accuracy comparable to existing state-of-the-art methods.
The C-Path Neuroscience Annual Workshop brought together stakeholders to chart a transformative course for neurology research and drug development, focusing on chronic progressive diseases such as Alzheimer's and Parkinson's. Key highlights included recommendations for innovative therapies and tools to address complex disorders.